Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : NASI (North American Scientific, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Westerner who wrote (577)	7/28/1998 10:21:00 PM
From: Seed Queen	Read Replies (1) \| Respond to of 658

Dear Westerner, Has NASI said if their focus will be on the Pd-103 market or on the I-125 market? Or both? It seems fair to say that they have their work cut out for them with Pd-103 seeds. Iodine might be a better focus. For any docs just starting a brachytherapy program (and the number in training courses continues to rise), it is very difficult to get I-125. The wait is long and patients don't like it. Clinical decisions about which isotope to use are being made on seed availability. I-125 for brachytherapy makes radiobiological "sense." The ideal situation obviously would be to have a ready supply to use based on the clinical situation. Are there patent issues to overcome for palladium production? Could that cause a long delay to production? Excuse my ignorance, but who is Gruverman? S.Q.